284 related articles for article (PubMed ID: 33328206)
1. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
Seok S; Sun H; Kim YC; Kemper B; Kemper JK
Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
[TBL] [Abstract][Full Text] [Related]
2. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition.
Lee J; Padhye A; Sharma A; Song G; Miao J; Mo YY; Wang L; Kemper JK
J Biol Chem; 2010 Apr; 285(17):12604-11. PubMed ID: 20185821
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.
Wu GY; Rui C; Chen JQ; Sho E; Zhan SS; Yuan XW; Ding YT
Cell Physiol Biochem; 2017; 44(4):1651-1664. PubMed ID: 29216638
[TBL] [Abstract][Full Text] [Related]
5. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice.
Kim KH; Choi S; Zhou Y; Kim EY; Lee JM; Saha PK; Anakk S; Moore DD
Hepatology; 2017 Aug; 66(2):498-509. PubMed ID: 28378930
[TBL] [Abstract][Full Text] [Related]
6. miR-188 promotes liver steatosis and insulin resistance via the autophagy pathway.
Liu Y; Zhou X; Xiao Y; Li C; Huang Y; Guo Q; Su T; Fu L; Luo L
J Endocrinol; 2020 Jun; 245(3):411-423. PubMed ID: 32252024
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
Kim YC; Jung H; Seok S; Zhang Y; Ma J; Li T; Kemper B; Kemper JK
Hepatology; 2020 Jun; 71(6):2118-2134. PubMed ID: 31549733
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
9. Transgenic mice lacking FGF15/19-SHP phosphorylation display altered bile acids and gut bacteria, promoting nonalcoholic fatty liver disease.
Kim YC; Qi M; Dong X; Seok S; Sun H; Kemper B; Fu T; Kemper JK
J Biol Chem; 2023 Aug; 299(8):104946. PubMed ID: 37348559
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor is essential for normal glucose homeostasis.
Ma K; Saha PK; Chan L; Moore DD
J Clin Invest; 2006 Apr; 116(4):1102-9. PubMed ID: 16557297
[TBL] [Abstract][Full Text] [Related]
11. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
12. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
13. miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
Fan L; Lai R; Ma N; Dong Y; Li Y; Wu Q; Qiao J; Lu H; Gong L; Tao Z; Chen J; Xie Q; Ren J
J Hepatol; 2021 Jan; 74(1):8-19. PubMed ID: 32818571
[TBL] [Abstract][Full Text] [Related]
14. The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice.
Myronovych A; Salazar-Gonzalez RM; Ryan KK; Miles L; Zhang W; Jha P; Wang L; Setchell KD; Seeley RJ; Kohli R
Obesity (Silver Spring); 2014 Nov; 22(11):2301-11. PubMed ID: 25376397
[TBL] [Abstract][Full Text] [Related]
15. The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP.
Fang S; Tsang S; Jones R; Ponugoti B; Yoon H; Wu SY; Chiang CM; Willson TM; Kemper JK
J Biol Chem; 2008 Dec; 283(50):35086-95. PubMed ID: 18842595
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
[TBL] [Abstract][Full Text] [Related]
17. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
Zhuge B; Li G
Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
[TBL] [Abstract][Full Text] [Related]
18. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
Li G; Kong B; Zhu Y; Zhan L; Williams JA; Tawfik O; Kassel KM; Luyendyk JP; Wang L; Guo GL
Toxicol Appl Pharmacol; 2013 Oct; 272(2):299-305. PubMed ID: 23811326
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
20. Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway.
Lim JY; Liu C; Hu KQ; Smith DE; Wang XD
Arch Biochem Biophys; 2018 Sep; 654():1-9. PubMed ID: 30006135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
